ALFA Finder| Value | ₹120.0 Cr |
|---|
BSE filing, NSE: KRSNAA. Summary written from the filing by ALFA Finder's alert engine.
Krsnaa Diagnostics Ltd: key numbers
- Share price
- ₹501.00
- Market cap
- ₹1,625 Cr
- Revenue (annual)
- ₹772.8 Cr
- Net profit (annual)
- ₹101.4 Cr
- P/E (TTM)
- 16.6×Sector 54.5×
- Promoter holding
- 27.11%+0.00% QoQ
- FII holding
- 3.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krsnaa Diagnostics Ltd
All →Krsnaa Diagnostics Other Announcement
Krsnaa Diagnostics informs exchanges that its RTA, KFin Technologies, will shift its corporate office effective December 1, 2026. The registered office and the company's own operations are unaffected.
Krsnaa Diagnostics Convertible Warrants
Krsnaa's auditor certified upfront consideration for 16.21 lakh promoter warrants at Rs.566 each, totalling Rs.91.75 Crore issue value. Certificate confirms upfront money came directly from allottees' accounts.
- Value
- ₹91.75 Cr
Krsnaa Diagnostics Bags New Order from Municipal Corporation of Delhi
Krsnaa Diagnostics secured a 15-year cash-based PPP project from the Municipal Corporation of Delhi. The contract involves establishing CT Scan and MRI facilities at three public hospitals.
- From
- Municipal Corporation of Delhi (MCD)
- Execution
- 15 years
- diagnostic facilities
- 3.0 project sites
Krsnaa Diagnostics Earnings Call Transcript: Key Takeaways
Krsnaa hit ₹500 Cr H1 revenue, but heavy Rajasthan ramp-up costs and government receivable delays (₹472 Cr) are squeezing margins and PAT.
- Call
- Guides 45% growth
Krsnaa Diagnostics Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 2,710 Mn (+32% YoY) and PAT INR 246 Mn (+3%). EBITDA margin fell to 27% from 29% on Rajasthan fixed costs.
Krsnaa Diagnostics Results Update
Krsnaa Diagnostics reported record Q2 revenue of Rs 2,710 million, up 32% year on year. H1 PAT fell to Rs 411 million on Rajasthan project costs.
Other merger & restructuring announcements
All →Zydus Lifesciences Merger & Restructuring
Zydus completed its subscription for 50% of Zydus Sunshine, making it a 50:50 joint venture with Sunshine Healthcare Lanka. Completed November 11, 2026.
Spacenet Enterprises India Merger & Restructuring Worth ₹2.6 Cr
Spacenet sold 40,00,005 String Metaverse shares on 11 November 2026 at ₹6.49 each. Gross consideration of about ₹2.60 Crore is disclosed as material.
- Value
- ₹2.60 Cr
Abans Financial Services Merger & Restructuring Worth ₹1.2 Cr
Abans Financial Services approved incorporating a Hong Kong subsidiary for bullion and securities trading. The cash consideration is Rs 1.20 Crore.
- Value
- ₹1.20 Cr
Adani Enterprises Merger & Restructuring Worth ₹0.94 Cr
Adani Enterprises reported incorporation of Adani Rovuma Chemicals Limited in UAE on November 10, 2026, via Adani Global Limited. Cash consideration of Rs. 0.94 Crore was stated.
- Value
- ₹0.94 Cr
Adani Enterprises Merger & Restructuring
Adani Enterprises' subsidiary Adani Global incorporated Adani Rovuma Chemicals Limited in UAE on November 10, 2026. It is a step-down subsidiary with USD 100,000 paid-up capital.
Kovai Medical Center and Hospital Merger & Restructuring Worth ₹0.85 Cr
Kovai Medical extended the completion deadline for the slump sale of its AHS division to a related-party trust to January 31, 2027. Cash consideration is Rs.84.54 Lakhs.
- Value
- ₹0.85 Cr
- Execution
- Completion expected by 31 January 2027